DOI QR코드

DOI QR Code

Analysis on Postoperative Efficacy of Radical Hepatectomy for Patients with Non-HBV/HCV Hepatocellular Carcinoma

  • Zhang, Zhi-Ming (Department of Hepatobiliary Surgery, The Affiliated Cancer Hospital of Guangxi Medical University) ;
  • Zhang, Yu-Mei (Department of Chemotherapy, The Affiliated Cancer Hospital of Guangxi Medical University) ;
  • Yao, Feng (Department of Hepatobiliary Surgery, The Affiliated Cancer Hospital of Guangxi Medical University) ;
  • Yi, Ping (Department of Hepatobiliary Surgery, The Affiliated Cancer Hospital of Guangxi Medical University) ;
  • Huang, Shang (Department of Hepatobiliary Surgery, The Affiliated Cancer Hospital of Guangxi Medical University) ;
  • Liu, Jian-Yong (Department of Hepatobiliary Surgery, The Affiliated Cancer Hospital of Guangxi Medical University) ;
  • Xiang, Bang-De (Department of Hepatobiliary Surgery, The Affiliated Cancer Hospital of Guangxi Medical University) ;
  • Yuan, Wei-Ping (Department of Hepatobiliary Surgery, The Affiliated Cancer Hospital of Guangxi Medical University) ;
  • Li, Le-Qun (Department of Hepatobiliary Surgery, The Affiliated Cancer Hospital of Guangxi Medical University)
  • Published : 2015.04.29

Abstract

Objective: Patients with hepatocellular carcinoma (HCC) in stage Barcelona Clinic Liver Cancer (BCLC)-A were grouped based on whether they were accompanied with hepatitis B virus (HBV) infection or not so as to explore the clinical characteristics and prognostic conditions of HCC patients with non-HBV/hepatitis C virus (HCV). Materials and Methods: Clinical data of 64 stage BCLC-A HCC patients with non-HBV/HCV infection (observation group) who received radical hepatectomy in the Affiliated Cancer Hospital of Guangxi Medical University from January, 2006 to November, 2014 were retrospectively analyzed and compared with those of 409 stage BCLC-A HCC patients with HBV infection (control group) in corresponding period. Results: The postoperative 1-, 3- and 5-year recurrent rates of the observation group were 25%, 38.6% and 48.8%, with postoperative mean and median disease-free survival time being 49.1 months and 62.0 months, respectively. Additionally, the postoperative 1-, 3- and 5-year survival rates of observation group were 90.1%, 72.7% and 62.0%, with the mean and median survival times being 54.4 months and 70.0 months, respectively. Conclusions: The 1-year recurrent rate is the highest in HCC patients with non-HBV/HCV, and almost half of the patients have recurrence within 1 year, after which the recurrent rate decreases along with the time.

Keywords

Non-HBV/HCV infection;hepatocellular carcinoma;hepatectomy

References

  1. Bruix J, Boix L, Sala M, et al (2004). Focus on Hepatocellular carcinoma. Cancer Cell, 5, 215-9. https://doi.org/10.1016/S1535-6108(04)00058-3
  2. Bruix J, Sala M, Llovet JM (2004). Chemoembolization for hepatocellular carcinoma. Gastroenterol, 127, S179-88. https://doi.org/10.1053/j.gastro.2004.09.032
  3. Calle EE, Rodriguez C, Walker-Thurmond K, et al (2003). Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med, 348, 1625-38. https://doi.org/10.1056/NEJMoa021423
  4. Carr BI, Guerra V, Steel JL, et al (2015). A Comparison of Patients With Hepatitis B- or Hepatitis C-Based Advanced-Stage Hepatocellular Carcinoma. Semin Oncol, 42, 309-315. https://doi.org/10.1053/j.seminoncol.2014.12.019
  5. Dai XZ, Yin HT, Sun LF, et al (2013). Potential therapeutic efficacy of curcumin in liver cancer.Asian Pac J Cancer Prev, 14, 3855-9. https://doi.org/10.7314/APJCP.2013.14.6.3855
  6. Fattovich G, Stroffolini T, Zagni I, et al (2004). Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterol, 127, S35-50. https://doi.org/10.1053/j.gastro.2004.09.014
  7. Graf D, Vallbohmer D, Knoefel WT, et al (2014). Multimodal treatment of hepatocellular carcinoma. Eur J Intern Med, 25, 430-7. https://doi.org/10.1016/j.ejim.2014.03.001
  8. Jeng JE, Tsai MF, Tsai HR, et al (2014). Impact of chronic hepatitis B and hepatitis C on adverse hepatic fibrosis inhepatocellular carcinoma related to betel quid chewing. Asian Pac J Cancer Prev, 15, 637-42. https://doi.org/10.7314/APJCP.2014.15.2.637
  9. Kar P (2014). Risk factors for hepatocellular carcinoma in India. J Clin Exp Hepatol, 4, S34-42.
  10. Kim MN, Han KH, Ahn SH (2015). Prevention of Hepatocellular Carcinoma: Beyond Hepatitis B Vaccination. Semin Oncol, 42, 316-28. https://doi.org/10.1053/j.seminoncol.2014.12.018
  11. Li X, Zhong X, Chen ZH, et al (2014). Hepatitis B virus DNA negativity acts as a favorable prognostic factor inhepatocellular carcinoma patients. Asian Pac J Cancer Prev, 15, 9635-41. https://doi.org/10.7314/APJCP.2014.15.22.9635
  12. Liu Y, Xie L, Zhao J, Huang X, et al (2015). Association between catalase gene polymorphisms and risk of chronic hepatitis B, hepatitis B virus-related liver cirrhosis and hepatocellular carcinoma in guangxi population: a case-control study. Medicine, 94, e702. https://doi.org/10.1097/MD.0000000000000702
  13. Maida M, Orlando E, Camma C, et al (2014). Staging systems of hepatocellular carcinoma: a review of literature. World J Gastroenterol, 20, 4141-50. https://doi.org/10.3748/wjg.v20.i15.4141
  14. Morise Z, Kawabe N, Tomishige H, et al (2014). Recent advances in the surgical treatment of hepatocellular carcinoma. World J Gastroenterol, 20, 14381-92. https://doi.org/10.3748/wjg.v20.i39.14381
  15. Norsa'adah B, Nurhazalini-Zayani CG (2013). Epidemiology and survival of hepatocellular carcinoma in north-east Peninsular Malaysia. Asian Pac J Cancer Prev, 14, 6955-9. https://doi.org/10.7314/APJCP.2013.14.11.6955
  16. Oyunsuren T, Sanduijav R, Davaadorj D, et al (2006). Hepatocellular carcinoma and its early detection by AFP testing in Mongolia. Asian Pac J Cancer Prev, 7, 460-2.
  17. Poon RT, Fan ST, Ng IO, et al (2000). Significance of resection margin in hepatectomy for hepatocellular carcinoma: A critical. Ann Surg, 231, 544-51. https://doi.org/10.1097/00000658-200004000-00014
  18. Ramesh H (2014). Resection for hepatocellular carcinoma. J Clin Exp Hepatol, 4, S90-6.
  19. Yamamoto Y, Ikoma H, Morimura R, et al (2015). Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomy. World J Gastroenterol, 21, 1207-15. https://doi.org/10.3748/wjg.v21.i4.1207
  20. Xu C, Lv PH, Huang XE, et al (2014). Safety and efficacy of sequential transcatheter arterial chemoembolization and portal vein embolization prior to major hepatectomy for patients with HCC.Asian Pac J Cancer Prev, 15, 703-6. https://doi.org/10.7314/APJCP.2014.15.2.703
  21. Yang X, Gao JY, Wang J, et al (2015). The impact of anti-HBV treatment on the occurrence and Recurrence ofhepatocellular carcinoma: focus on Asian studies. Discov Med, 19, 89-99.
  22. Zhu WJ, Huang CY, Li C, et al (2013). Risk factors for early recurrence of HBV-related hepatocellular carcinoma meeting Milan criteria after curative resection. Asian Pac J Cancer Prev, 14, 7101-6. https://doi.org/10.7314/APJCP.2013.14.12.7101

Cited by

  1. Diagnostic Value of the Combination of Golgi Protein 73 and Alpha-Fetoprotein in Hepatocellular Carcinoma: A Meta-Analysis vol.10, pp.10, 2015, https://doi.org/10.1371/journal.pone.0140067